References
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med. 2018 February 1;378(5):437–448.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 December 28;377(26):2531–2544.
- Moher D, Liberati A, Tetzlaff J, et al. The PRISMA group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.
- Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtageneciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245. .
- Lin VW, Jiang Y, Chuang LH, et al. Health utilities for patients with relapsed or refractory large B-cell lymphoma: ad hoc analysis from an axicabtagene ciloleucel safety management study. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation, Lisbon, Portugal. 2018.
- Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172(12):1161–1168.
- US Food and Drug Administration. Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed/refractory b-bell acute lymphoblastic leukemia. FDA Advisory Committee Briefing Document.Washington, DC: US Food and Drug Administration; 2017.
- Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24(12):1917.
- Lin JK, Lerman BJ, Barnes JI, et al. Fiebert cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192.
- Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. JNCI J Natl Cancer Inst. 2019;111(7):1–8.
- Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118(23):6043–6049.
- Yang H, Qi C, Zhang J, et al. Cost-effectiveness of tisagenlecleucel for adults with relapsed or refractory diffuse large b-cell lymphoma: a canadian societal perspective. Barcelona, Spain; 2018 Nov.
- Yang H, Zhang J, Hampe M. Cost-effectiveness of tisagenlecleucel in pediatric and young adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia: a canadian societal perspective. Barcelona, Spain; 2018 Nov. Code: PCN170 ISPOR Europe 2018
- Marchetti M, Martelli E, Zinzani PL. Cost-effectiveness of axicabtagene ciloleucel for relapsed or refractory diffuse large B-cell lymphoma in Italy. Blood. 2018;132:4779.
- Bae YHJ, Mullins CD. Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Spec Pharm. 2014 November;20(11):1086–1092.
- Hollmann S, Painter C, Hogan A et al. Budget impact analysis of tisagenlecleucel for the treatment of paediatric and young adult patients with relapsed or refractory b-cell acute lymphoblastic leukaemia in England. Barcelona Spain; 2018 Nov. Code: PCN68 ISPOR Europe 2018.
- Car T-cell therapies in France PPRI Webinar – 13 February. Jonathan Rodrigues assessed in February 2019.
- NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Final appraisal document Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. [cited 2019 May]. Available from: https://www.nice.org.uk/guidance/ta554/documents/final-appraisal-determination-document
- Kefalas P, Ali O, Jørgensen J, et al. Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy. J Mark Access Health Policy. 2018;6:1511679.
- Entela Xoxi Agenda item 4. Real world evidence data collection Italian Experience on Registries Commission expert group on “Safe and Timely Access to Medicines for Patients”(STAMP) Brussels. 2016 Mar 10.
- Petrou P. The quest for the in medio stat virtus price in the oncology sector. J Med Econ. 2018;21(10):1023–1025.
- Zheng P-P, Kros JM, Li J. Approved CAR T cell therapies ice bucket challenges on glaring safety risks and long term impacts. Drug Discov Today. 2018 June;23(6):1175–1182.
- Ofman E, Sullivan S, Neumann P, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003 January/February;9(1):53–61.